Welcome to the e-CCO Library!

P484: Access to biologics and biosimilars across 11 European Union countries
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Lakatos*1, E. Domenech2, H. Kellner3, J. Marsal4, H. Fowler5, C. Agboton5, N. Georgitseas6, M. Cassese7, S. Anwar6, A. Venugopal7, P. Audhya5

Created: Friday, 22 February 2019, 9:49 AM
P484: Dietary therapy using the Crohn's disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sigall Boneh R.*1, Sarbagili Shabat C.1, Boaz M.2,3, Levine A.1,4, Chermesh I.5, Ben Avraham S.1, Cohen Dolev N.1

Created: Wednesday, 20 February 2019, 10:36 AM
P484: Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
Year: 2022
Source: ECCO'22
Authors: Levartovsky, A.(1);Cohen, I.(1);Abitbol, C.M.(1);Yavzori, M.(1);Fudim, E.(1);Picard, O.(1);Kopylov, U.(1);Ben-Horin, S.(1);Ungar, B.(1);
Created: Friday, 11 February 2022, 3:56 PM
P484: Hepatitis B vaccination in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Cortez Pinto*1, J. Castela1, J. Moleiro1, J. Pereira da Silva1, I. Rosa1, A. Dias Pereira1

Created: Friday, 22 February 2019, 9:41 AM
P484: Inflammatory Bowel Disease exercise and diet habits (IBDeat) study: chronic metabolic disease risk factors among IBD patients in New Zealand
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yap, J.(1)*;Wall, C.(2);Meredith-Jones, K.(1);Iosua, E.(1);Osborne, H.(1);Schultz, M.(1);
Created: Friday, 14 July 2023, 11:05 AM
P484: Infliximab and vedolizumab show a different effect on clot formation in inflammatory bowel disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

I. Detrez1*, V. Ballet2, M. Peeters1, G. Van Assche2, S. Vermeire2, M. Ferrante2, A. Gils1

Created: Thursday, 21 February 2019, 9:14 AM
P484: Remote monitoring allows an individualized approach and showed excellent usability at the infusion unit
Year: 2021
Source: ECCO'21 Virtual
Authors: Fierens, L.(1);Geens, P.(2);De Dycker, E.(2);Paps, A.(2);Lambrechts, T.(2);Sabino, J.(1,2);Vermeire, S.(1,2);Ferrante, M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P485 Switching infliximab biosimilar: No adverse impact on inflammatory bowel disease control or drug levels with the first or second switch
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Luber1, R. O’Neill2, S. Singh2, Z. Arkir3, P. Irving1

Created: Thursday, 30 January 2020, 10:12 AM
P485: An Assessment Of A Guided Self-Help and Patient Initiated Review Pathway for Ulcerative Proctitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Saunders, J.(1)*;Maroo, S.(1);Brownson, E.(1);Boulton Jones, R.(1);
Created: Friday, 14 July 2023, 11:05 AM
P485: Apolipoprotein C3 is Downregulated in Patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Hernandez Camba, A.(1);Carrillo Palau, M.(2);Ramos, L.(2);Alonso, I.(2);Vela, M.(1);Hernández, A.(2);Arranz , L.(1);Hernández, N.(2);Hernández-Guerra, M.(2);Ferráz, I.(3);
Created: Friday, 11 February 2022, 3:56 PM
P485: Development and implementation of a remote monitoring tool for real-world assessment of mild, moderate and severe infectious complications in Inflammatory Bowel Disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Rezazadeh Ardabili, A.(1,2);Wintjens, D.S.J.(1,2);Mujagic, Z.(1,2);Cilissen, M.(1);Stassen, L.P.S.(3);Haans, J.J.L.(1);Jonkers, D.M.A.E.(1,2);Pierik, M.J.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P485: Dosing infliximab in Crohn's disease: Is adjustment for body size justified?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Grisic A.-M.*1,2, Huisinga W.3, Reinisch W.4, Kloft C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P485: Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Vande Casteele*1,2, V. Jairath2,3,4, J. Jeyarajah2, P. S. Dulai1,2, S. Singh1, B. G. Feagan2,3,4, W. J. Sandborn1,2

Created: Friday, 22 February 2019, 9:41 AM
P485: Real-world evidence (RWE) on outcomes and clinical treatment patterns of 5-aminosalicylic acid (5-ASA) in mild Crohn’s disease (CD) from European healthcare databases (the CROHN’S investigation)
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Paridaens1, Y.L. Yip1, O. Ghatnekar2, M. Plassais1, J. Edwards3, J. Kuiper4, B. Rodgers-Grey3*, S. Buchan3

Created: Thursday, 21 February 2019, 9:14 AM
P485: The combined of mesenchymal stem cells and infliximab reduces the recurrence rate of Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

O. Knyazev1, N. Fadeeva*2, A. Kagramanova1, P. Shcherbakov3, I. Ruchkina1, A. Parfenov1, A. Konoplyannikov4

Created: Friday, 22 February 2019, 9:49 AM
P486 Assessing the efficacy of biologics in ucerative colitis: a real-life, observational retrospective multicentre study with propensity score analysis (AURORA): Focus on patients naive to biologics
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Cassinotti1, N. Mezzina1, D. Di Paolo2, M.V. Lenti3, C. Bezzio4, D. Stradella5, M. Mauri6, V. Zadro1, C. Cortellezzi7, C. Ricci8, V. Casini9, E. Radice10, A. Massari1, S. Ardizzone1, L. Pastorelli2, A. Di Sabatino3, G. Manes4, F. Caprioli11, M. Vecchi11, R. Tari5, P. Occhipinti5, M. Fichera6, P. Invernizzi6, M. Parravicini7, S. Segato7, F. Pace9, P.A. Testoni10, C. Tinelli12, A. De Silvestri12

Created: Thursday, 30 January 2020, 10:12 AM
P486: Faecal microbiota transplantation in inflammatory bowel disease: the patient's perspective
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Sousa*1, A. Ponte1, J. Rodrigues1, J. Silva1, C. Gomes1, A. Rodrigues1, A. P. Silva1, J. Carvalho1

Created: Friday, 22 February 2019, 9:41 AM
P486: Immunization status of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Cagol L.1, Frivolt K.2, Krahl A.3, Förster N.3, Lainka E.4, Gerner P.5, Ney D.6, Vermehren J.7, Trenkel S.8, Radke M.8, Koletzko S.2, Posovszky C.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P486: Improving enhanced recovery after surgery (ERAS): the effect of a patient-centred mobile application on patient participation in colorectal surgery
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Van Der Storm, S.(1)*;Jansen, M.(1);Marsman, H.A.(2);Molly, G.P.(3);Consten, E.C.(4);Groot, L.M.(4);Boer, F.C.(5);Corver, M.(5);Oosterling, S.J.(6); Tuynman, J.B.(7);Bemelman, W.A.(1);Buskens, C.J.(1);Schijven, M.P.(1);
Created: Friday, 14 July 2023, 11:05 AM
P486: Intrapatient variability in adalimumab drug levels within and across cycles in Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Ward*1, 2, L. Beswick2, P. Thwaites1, J. Hogg1, G. Rosella3, J. Reynolds4, D. Van Langenberg2, P. Gibson1, 3, M. Sparrow1, 3

Created: Friday, 22 February 2019, 9:49 AM